The further evolution of hyperparathyroidism Kleerekoper M Am J Med 2004; 117: 884-6 A recent contribution to Journal Watch reviewed developments in the diagnosis and management of hyperparathyroidism --new immunoassays for parathyroid hormone (PTH) fragments, innovative imaging techniques for localization prior to surgical exploration, and new approaches to medical treatment with calcimimetic drugs. A further aspect of hyperparathyroidism --or, to use the jargon employed in a recent article,'peeling back the onion' --is highlighted in this editorial. The author discusses the changing 'portal of entry of primary hyperparathyroidism' in clinical medicine. The days when patients came to clinical attention with symptomatic hyperparathyroidism are gone. So too is the serendipitous case-¢nding of unsuspected hypercalcaemia via non-selective biochemical pro¢ling. What the author is referring to now is the detection of unsuspected hyperparathyroidism in the biochemical work-up of patients found to have reduced bone mineral density. Some of these patients are found to have increased PTH but normal calcium concentrations --thus describing a new disease entity of normocalcaemic primary hyperparathyroidism. This rather contentious condition has been suspected for some time, but it is the recent research published in the same edition of the journal which provides de¢nitive con¢rmation. In a number of Israeli women investigated for reduced bone mineral density, hyperparathyroidism with normal plasma calcium was documented.
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None of the other common causes of hyperparathyroidism, including vitamin D de¢ciency, were identi¢ed in these essentially asymptomatic menopausal women, nor was there any evidence of idiopathic hypercalciuria as a cause of secondary hyperparathyroidism.
Having identi¢ed a disease process essentially in the presymptomatic stage, how is the clinician to treat it? Well, the American Guidelines (J Clin Endocrinol Metab 2002; 87: 5353--61) only advocate surgery for asymptomatic primary hyperparathyroidism if the bone mineral density is two or more standard deviations below the mean. Nor should surgery be such a drastic option with the advent of improved preoperative localization and intraoperative PTH assays and minimally invasive parathyroidectomy conducted under local anaesthetic as day surgery. To complement the surgical approach, bone mineral density can be preserved with antiresorption medication and the calcimimetic drugs can be used to reduce hypercalcaemia if present.
So the burden of recognition of this new category of asymptomatic patients with hyperparathyroidism but without hypercalcaemia is alleviated by the improvements in both medical and surgical treatment of the condition.
Who would have thought that the e¡orts of dedicated scientists developing the second generation of PTH immunoassays two decades ago would have spawned a diagnostic industry dedicated to one endocrine gland!
Helen Losty Southend
Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B: relationships among the different measurements Franzini C, Valente C, Luraschi P Scand J Clin Lab Invest 2004; 64: 703-8
Low-density lipoprotein cholesterol (LDL) has long been used as a predictor of cardiovascular disease and as a recommended treatment target for the prevention of atherosclerotic disease and its complications. Recent work, however, has shown non-high-density lipoprotein cholesterol (non-HDL), which represents all circulating ApoB-containing lipoprotein, to be a better predictor of cardiovascular risk in both the general population and diabetics.
Most laboratories do not measure LDL or non-HDL directly. Non-HDL is derived by simply subtracting measured HDL cholesterol from measured total cholesterol (TC), whereas LDL is calculated using the Friedewald equation (LDL ¼ TCÀHDLÀ0.458TG), which is known to underestimate LDL values at high triglyceride (TG) concentrations (43.96 mmol/L).
In this article, Franzini et al. are able to show a weak negative correlation between LDL and TG but no signi¢cant correlation between non-HDL and TG concentration. They also show that, while both LDL and non-HDL are signi¢cantly correlated with ApoB, the association is stronger for non-HDL than LDL. Furthermore, as TG levels increase, there is a fall in the LDL/ApoB ratio, further weakening the correlation. This e¡ect is not seen with HDL. The ¢ndings presented here are not new, which raises the question: should biochemistry labs be moving away from LDL and the Friedewald equation and towards the simpler, more reliable non-HDL? Polycystic ovary syndrome (PCOS) is one of the most common hormonal disorders in women, with a prevalence of between 5 and 10%. Initially described as a syndrome of 'amenorrhoea, hirsutism, obesity and a characteristic polycystic appearance to the ovaries', it is now known to have serious e¡ects on reproductive, metabolic and cardiovascular health. This excellent review by David Ehrmann gives a comprehensive update of the syndrome from diagnosis to treatment.
Once all other causes of irregular menses and androgen excess have been excluded, diagnosis depends on the presence of two of the following: oligo-/anovulation, elevated androgen levels and polycystic ovaries on ultrasound scan. The role of the biochemistry laboratory is well established in the investigation of PCOS, with typical ¢ndings including increased luteinizing hormone levels and/or an increased LH:FSH ratio, hyperandrogenism and hyperinsulinism.
As a part of the metabolic syndrome, the PCOS phenotype includes obesity, impaired glucose tolerance, diabetes and an atherogenic lipid pro¢le. Assessment of women with PCOS should therefore include the oral glucose tolerance test, although controversy persists as to whether all women should be screened or just those at particularly high risk. As for assessing insulin resistance, there seems little to support its use outside of clinical trials.
The treatment of PCOS is aimed at minimizing insulin resistance and reducing cardiovascular risk through weight reduction, Metformin or the thiazolidenediones. Treatments for symptomatic hyperandrogenism are also discussed.
